Division of Neuroscience and Experimental Psychology, Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Division of Cardiovascular Sciences, Lydia Becker Institute of Immunology and Inflammation, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Int J Stroke. 2021 Feb;16(2):123-136. doi: 10.1177/1747493020972240. Epub 2020 Nov 13.
Intracerebral hemorrhage is a devastating global health burden with limited treatment options and is responsible for 49% of 6.5 million annual stroke-related deaths comparable to ischemic stroke. Despite the impact of intracerebral hemorrhage, there are currently no effective treatments and so weaknesses in the translational pipeline must be addressed. There have been many preclinical studies in intracerebral hemorrhage models with positive outcomes for potential therapies , but beyond advancing the understanding of intracerebral hemorrhage pathology, there has been no translation toward successful clinical application. Multidisciplinary preclinical research, use of multiple models, and validation in human tissue are essential for effective translation. Repurposing of therapeutics for intracerebral hemorrhage may be the most promising strategy to help relieve the global health burden of intracerebral hemorrhage. Here, we have reviewed the existing literature to highlight repurposable drugs with successful outcomes in preclinical models of intracerebral hemorrhage that have realistic potential for development into the clinic for intracerebral hemorrhage.
脑出血是一种具有全球破坏性的健康负担，治疗选择有限，占每年 650 万例与中风相关死亡人数的 49%，与缺血性中风相当。尽管脑出血的影响很大，但目前还没有有效的治疗方法，因此必须解决转化途径中的弱点。在脑出血模型中有许多临床前研究，为潜在的治疗方法带来了积极的结果，但除了推进对脑出血病理的理解之外，这些研究还没有转化为成功的临床应用。多学科的临床前研究、使用多种模型以及在人体组织中的验证对于有效的转化至关重要。脑出血治疗药物的再利用可能是帮助缓解脑出血这一全球健康负担的最有前途的策略。在这里，我们回顾了现有的文献，重点介绍了在脑出血的临床前模型中取得成功结果的可再利用药物，这些药物具有切实的发展为脑出血临床治疗的潜力。
